Company intelligence / Profile preview

Glenmark Pharmaceuticals

Mumbai, Maharashtra, Indiaglenmarkpharma.com ↗

Ownership: Private
Employees: ~15000
Development stage: Commercial

Overview

Glenmark has a robust pipeline of specialty products and innovative molecules in various stages of clinical development across oncology and immunology. The company recently launched a biosimilar variant of the anti-diabetic drug Liraglutide in India and introduced Abrocitinib (JABRYUS) for atopic dermatitis in collaboration with Pfizer.

Therapeutic areas: PulmonologyCardiovascularEndocrinologyImmunologyDermatologyOncologyInfectious Diseases
Modalities: Small moleculesbiologics
Industry: Biotech

Drug pipeline

18 assets

potassium phosphates injection

17 more assets in the full pipeline.

Request access →

Partnerships

PfizerJiangsu Alphamab Biopharmaceuticals3D MedicinesSequirusMerck KGaAEli LillyForest LaboratoriesTeijin Pharma

Beyond the preview

Go deeper on Glenmark Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glenmark Pharmaceuticals.

Explore the full profile